- The Mallinckrodt Group has received US Food and Drug Administration approval to market two new analgesics. The first, oral Anexia (acetominophen/hydrocodone), was set to be introduced on September 1 in 10/660mg doses to treat moderate-to-moderately severe pain. The second product, prefilled syringes of one-dose UltraJect (morphine sulfate), is scheduled for release on the market in January 1997. It is approved in two strengths, and is the first patient-controlled syringe for moderate-to-severe pain relief.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze